The increasing complexity of emerging technologies needed for drug discovery demands bigger players who can bring them together on one platform to optimize for best possible results. Evotec AG says that megatrend lies behind its purchase of the CRO Aptuit, creating a "one-stop-shop" for external innovation.
"The rationale behind this acquisition is to give everyone the option to go much faster on a very clear path...








